InvestorsHub Logo
Followers 130
Posts 5096
Boards Moderated 6
Alias Born 04/12/2010

Re: JohnnieWalker post# 172

Tuesday, 10/13/2020 10:36:41 AM

Tuesday, October 13, 2020 10:36:41 AM

Post# of 389
Global Phase 3 Clinical Trials of Vadadustat vs. Darbepoetin Alfa for Treatment of Anemia in Patients with Dialysis-Dependent CKD



BACKGROUND
Vadadustat (VADA) is an investigational, oral, hypoxia-inducible factor prolyl hydroxylase inhibitor that has advanced to phase 3 development for treatment of anemia of CKD. In phase 2 trials, VADA raised and maintained Hb concentrations.

METHODS
Two randomized, phase 3, global, open-label, sponsor-blind, parallel-group active-controlled noninferiority (NI) trials comparing VADA vs darbepoetin alfa (DA) were conducted in patients with anemia of DD-CKD (INNO2VATE trials). The trials included 1) Correction/Conversion trial of patients new to dialysis (incident trial, NCT02865850) and 2) Conversion trial of patients on maintenance dialysis (prevalent trial, NCT02892149). The primary safety endpoint was time to first major adverse cardiovascular event (MACE: all-cause mortality, nonfatal MI, nonfatal stroke) prespecified as a pooled analysis of both trials. Primary and key secondary efficacy endpoints, prespecified as separate analyses for each trial, were mean difference in change in Hb from baseline between VADA vs DA to wks 24-36 and wks 40-52, respectively.

RESULTS
3923 patients were randomized 1:1 to VADA or DA (incident, N=369; prevalent, N=3554). Median (Q1, Q3) duration of follow-up was 1.2 (0.8, 1.7) and 1.7 (1.2, 2.2) years in the incident and prevalent trials, respectively. VADA was noninferior to DA for time to first MACE (HR 0.96; 95% CI: 0.83, 1.11) and met a prespecified NI margin of 1.25. Among incident dialysis patients, the least squares (LS) mean difference in change in Hb between VADA vs DA from baseline to wks 24-36 was -0.31 g/dL (95% CI: -0.53, -0.10) and from wks 40-52 was -0.07 g/dL (95% CI: -0.34, 0.19). In the prevalent trial, the LS mean difference in change in Hb from baseline to wks 24-36 was -0.17 g/dL (95% CI: -0.23, -0.10), and wks 40-52 was -0.18 g/dL (95% CI: -0.25, -0.12). Primary and key secondary efficacy endpoints met the prespecified NI margin of -0.75 g/dL in both trials. Incidence of treatment-emergent adverse events (TEAEs) in VADA vs DA was 83.8% vs 85.5% in the incident trial and 88.3% vs. 89.3% in the prevalent trial, respectively.

CONCLUSION
VADA was noninferior to DA in time to first MACE and correction/maintenance of Hb in DD-CKD patients with anemia. The incidence of TEAEs was comparable between VADA and DA.

https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3441404





I am not a professional and my opinions are just that, opinions.
Please do not buy based on my recommendations, do you own DD.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AKBA News